• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经肺途径的肿瘤标志物在肺癌早期诊断中的应用潜力:一例报告。

Potential for trans-pulmonary tumor markers in the early diagnosis of lung cancer: a case report.

机构信息

Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 1215 21st Avenue - Medical Center East - 5th Floor, Nashville, TN, 37232, USA.

Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

出版信息

BMC Pulm Med. 2024 Sep 18;24(1):460. doi: 10.1186/s12890-024-03288-z.

DOI:10.1186/s12890-024-03288-z
PMID:39294582
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11409683/
Abstract

BACKGROUND

Measurement of tumor markers from peripheral venous blood is an emerging tool to assist in the early diagnosis of lung cancer. Samples from the pulmonary artery and pulmonary artery wedge position (trans-pulmonary samples) are accessible via right-heart catheterization and, by virtue of their proximity to lung tumors, may increase diagnostic yield.

CASE PRESENTATION

We report a case of a 64 year-old woman from whom trans-pulmonary samples were obtained and who was diagnosed 16 months later with recurrent metastatic small cell lung cancer. Carcinoembryonic antigen, cytokeratin fragment 21 - 1 (CYFRA), and human epididymis protein 4 (HE4) levels demonstrated increasing concentrations across the pulmonary circulation. These gradients exceeded the assays' coefficient of variation by several-fold. For CYFRA and HE4, pulmonary artery wedge concentrations exceeded peripheral venous levels by more than 10% and peripheral arterial levels were up to 8% higher than peripheral venous levels.

CONCLUSIONS

Evaluating the feasibility and utility of trans-pulmonary tumor markers for lung cancer diagnosis in a larger cohort should be considered. The addition of a peripheral arterial sample to standard peripheral venous samples may be a more practical alternative.

摘要

背景

从外周静脉血测量肿瘤标志物是一种新兴的工具,可以帮助早期诊断肺癌。通过右心导管可以获得肺动脉和肺动脉楔位(经肺样本)的样本,由于它们靠近肺肿瘤,因此可能会提高诊断率。

病例介绍

我们报告了一例 64 岁女性的病例,从她那里获得了经肺样本,16 个月后被诊断为复发性转移性小细胞肺癌。癌胚抗原、细胞角蛋白片段 21-1(CYFRA)和人附睾蛋白 4(HE4)的水平在整个肺循环中呈浓度递增。这些梯度超过了测定的变异系数几倍。对于 CYFRA 和 HE4,肺动脉楔位浓度超过外周静脉水平超过 10%,而外周动脉水平比外周静脉水平高 8%。

结论

应考虑在更大的队列中评估经肺肿瘤标志物用于肺癌诊断的可行性和实用性。将外周动脉样本添加到标准外周静脉样本中可能是一种更实用的替代方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a32/11409683/c06cf3d07dd3/12890_2024_3288_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a32/11409683/c06cf3d07dd3/12890_2024_3288_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a32/11409683/c06cf3d07dd3/12890_2024_3288_Fig1_HTML.jpg

相似文献

1
Potential for trans-pulmonary tumor markers in the early diagnosis of lung cancer: a case report.经肺途径的肿瘤标志物在肺癌早期诊断中的应用潜力:一例报告。
BMC Pulm Med. 2024 Sep 18;24(1):460. doi: 10.1186/s12890-024-03288-z.
2
Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.使用肿瘤标志物细胞角蛋白片段21.1(CYFRA 21.1)、人附睾蛋白4(HE4)和胃泌素释放肽前体(ProGRP)进行三联检测可能有助于肺癌的诊断和亚型分类。
Clin Biochem. 2018 Aug;58:15-19. doi: 10.1016/j.clinbiochem.2018.05.001. Epub 2018 May 2.
3
The Application Value of Serum HE4 in the Diagnosis of Lung Cancer.血清人附睾蛋白4在肺癌诊断中的应用价值
Asian Pac J Cancer Prev. 2019 Aug 1;20(8):2405-2407. doi: 10.31557/APJCP.2019.20.8.2405.
4
Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer.小细胞肺癌患者中的人附睾蛋白4(HE4)
Clin Lab. 2016 Sep 1;62(9):1625-1632. doi: 10.7754/Clin.Lab.2016.151212.
5
New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?肺癌血清标志物的诊断特征和临床应用的新见解,人附睾蛋白 4 作为一种新的标志物?
Neoplasma. 2022 May;69(3):729-740. doi: 10.4149/neo_2022_220207N144. Epub 2022 Apr 26.
6
Age-stratified and gender-specific reference intervals of six tumor markers panel of lung cancer: A geographic-based multicenter study in China.基于地理的中国多中心研究:肺癌六种肿瘤标志物panel 的年龄分层和性别特异性参考区间。
J Clin Lab Anal. 2021 Jun;35(6):e23816. doi: 10.1002/jcla.23816. Epub 2021 May 12.
7
Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.基于血液的生物标志物细胞角蛋白 19 片段(CYFRA 21-1)和人附睾蛋白 4(HE4)在肺腺癌手术后监测复发中的应用潜力。
Lung Cancer. 2019 Apr;130:194-200. doi: 10.1016/j.lungcan.2019.02.017. Epub 2019 Feb 19.
8
Biomarkers in the lung cancer diagnosis: a clinical perspective.肺癌诊断中的生物标志物:临床视角。
Neoplasma. 2012;59(5):500-7. doi: 10.4149/neo_2012_064.
9
New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.肺癌鉴别诊断中的新型和传统生物标志物:胃泌素释放肽与神经元特异性烯醇化酶、癌胚抗原和细胞角蛋白 19 片段 21-1 的比较。
Int J Biol Markers. 2019 Jun;34(2):163-167. doi: 10.1177/1724600819834235. Epub 2019 Apr 17.
10
[Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].血清癌胚抗原和细胞角蛋白19片段在肺癌患者中的检测及诊断价值
Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):847-9.

本文引用的文献

1
Update on Biomarkers for the Stratification of Indeterminate Pulmonary Nodules.肺结节良恶性评估的生物标志物研究进展。
Chest. 2023 Oct;164(4):1028-1041. doi: 10.1016/j.chest.2023.05.025. Epub 2023 May 25.
2
Liquid biopsy-based decision support algorithms for diagnosis and subtyping of lung cancer.基于液体活检的肺癌诊断和亚型分类决策支持算法
Lung Cancer. 2023 Apr;178:28-36. doi: 10.1016/j.lungcan.2023.01.014. Epub 2023 Feb 1.
3
Improving malignancy risk prediction of indeterminate pulmonary nodules with imaging features and biomarkers.
利用影像学特征和生物标志物提高肺内不定性结节恶性风险预测能力。
Clin Chim Acta. 2022 Sep 1;534:106-114. doi: 10.1016/j.cca.2022.07.010. Epub 2022 Jul 20.
4
Integrated Biomarkers for the Management of Indeterminate Pulmonary Nodules.用于处理肺结节不明确情况的综合生物标志物
Am J Respir Crit Care Med. 2021 Dec 1;204(11):1306-1316. doi: 10.1164/rccm.202012-4438OC.
5
Non-invasive early detection of cancer four years before conventional diagnosis using a blood test.利用血液检测,可在常规诊断前四年进行非侵入性的癌症早期检测。
Nat Commun. 2020 Jul 21;11(1):3475. doi: 10.1038/s41467-020-17316-z.
6
Noninvasive biomarkers for lung cancer diagnosis, where do we stand?用于肺癌诊断的非侵入性生物标志物,我们目前处于什么阶段?
J Thorac Dis. 2020 Jun;12(6):3317-3330. doi: 10.21037/jtd-2019-ndt-10.
7
Using arterial-venous analysis to characterize cancer metabolic consumption in patients.采用动静脉分析方法来描述患者的癌症代谢消耗。
Nat Commun. 2020 Jun 23;11(1):3169. doi: 10.1038/s41467-020-16810-8.
8
Biomarker-specific differences between transpulmonary and peripheral arterial-venous blood sampling in patients with pulmonary hypertension.肺高压患者经肺和外周动静脉血样间生物标志物的特异性差异。
Biomarkers. 2020 Mar;25(2):131-136. doi: 10.1080/1354750X.2019.1710256. Epub 2020 Jan 9.
9
The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension.在左心室射血分数保留且合并毛细血管前和毛细血管后肺动脉高压的患者中,内皮素-1的跨肺比值升高。
Pulm Circ. 2018 Jan-Mar;8(1):2045893217745019. doi: 10.1177/2045893217745019. Epub 2017 Dec 18.